Dwanaście powodów, dla których warto stosować terapię skojarzoną atorwastatyną i amlodypiną – przegląd doniesień naukowych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2014
Słowa kluczowe:
nadciśnienie tętnicze, dyslipidemia, amlodypina, atorwastatyna, preparat złożony
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze i dyslipidemia należą do głównych czynników ryzyka umieralności i chorobowości z przyczyn sercowo-naczyniowych. Pacjenci przyjmujący leki hipotensyjne często wymagają również jednoczesnego podawania leków hipolipemizujących. Preparat łączony zawierający amlodypinę i atorwastatynę stanowi nową opcję terapeutyczną dla chorych z nadciśnieniem tętniczym i współistniejącą dyslipidemią lub chorobą niedokrwienną serca. Artykuł przedstawia 12 powodów, dla których warto taki właśnie lek stosować w codziennej praktyce klinicznej.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2014). Dwanaście powodów, dla których warto stosować terapię skojarzoną atorwastatyną i amlodypiną – przegląd doniesień naukowych. Medycyna Faktów , 7(3(24), 25-30. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2349
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McKeage K., Siddiqui M.A.A.: Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am. J. Cardiovasc. Drugs 2008; 8: 51-67.
2. Wong N.D., Lopez V., Tang S. et al.: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am. J. Cardiol. 2006; 98: 204-208.
3. MacDonald T.M., Morant S.V.: Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br. J. Clin. Pharmacol. 2008; 65: 775-786.
4. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
5. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
6. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
7. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk Manag. 2008; 4: 673-678.
8. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees BMC Cardiovasc. Disord. 2010; 10: 29.
9. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-2685.
10. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-137.
11. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
12. Charbonneau F., Anderson T.J., Title L. et al.: Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 2008; 197: 420-427.
13. Ge C.J., Lu SZ, Chen Y.D. et al.: Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
14. Fogari R., Preti P., Zoppi A. et al.: Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 2006; 62: 817-822.
15. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146: 319-325.
16. Fogari R., Derosa G., Lazzari P. et al.: Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 2004; 17: 823-827.
17. Trion A., de Maat M., Jukema W. et al.: Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/ hCRP transgenic mice. J. Cardiovasc. Pharmacol. 2006; 47: 89-95.
18. van de Poll S.W., Delsing D.J., Jukema J.W. et al.: Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164: 65-71.
19. Martin-Ventura J.L., Munoz-Garcia B., Blanco-Colio L.M et al.: Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl. 2008; 111: S71-S74.
20. Cohn J.N., Wilson D.J., Neutel J. et al.: Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 2009; 22: 137-144.
21. Leibovitz E., Beniashvili M., Zimlichman R. et al.: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003; 16: 715-718..
2. Wong N.D., Lopez V., Tang S. et al.: Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am. J. Cardiol. 2006; 98: 204-208.
3. MacDonald T.M., Morant S.V.: Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br. J. Clin. Pharmacol. 2008; 65: 775-786.
4. Masson R.P.: Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor. Drugs 2008; 68: 885-900.
5. Chapman R.H., Benner J.S., Petrilla A.A. et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005; 180: 137-143.
6. Bangalore S., Kamalakkannan G., Parkar S. et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120: 713-719.
7. Patel B.V., Leslie R.S., Thiebaud P. et al.: Adherence with single pill amlodipine/atorvastatin vs two pill regimen. Vasc. Health Risk Manag. 2008; 4: 673-678.
8. Chapman R.H., Yeaw J., Roberts C.S.: Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees BMC Cardiovasc. Disord. 2010; 10: 29.
9. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-2685.
10. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-137.
11. Mason R.P., Kubant R., Heeba G. et al.: Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008; 25: 1798-1806.
12. Charbonneau F., Anderson T.J., Title L. et al.: Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 2008; 197: 420-427.
13. Ge C.J., Lu SZ, Chen Y.D. et al.: Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
14. Fogari R., Preti P., Zoppi A. et al.: Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur. J. Clin. Pharmacol. 2006; 62: 817-822.
15. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146: 319-325.
16. Fogari R., Derosa G., Lazzari P. et al.: Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am. J. Hypertens. 2004; 17: 823-827.
17. Trion A., de Maat M., Jukema W. et al.: Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/ hCRP transgenic mice. J. Cardiovasc. Pharmacol. 2006; 47: 89-95.
18. van de Poll S.W., Delsing D.J., Jukema J.W. et al.: Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164: 65-71.
19. Martin-Ventura J.L., Munoz-Garcia B., Blanco-Colio L.M et al.: Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int. Suppl. 2008; 111: S71-S74.
20. Cohn J.N., Wilson D.J., Neutel J. et al.: Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am. J. Hypertens. 2009; 22: 137-144.
21. Leibovitz E., Beniashvili M., Zimlichman R. et al.: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003; 16: 715-718..